UPClytics
EnglishDeutsch
Sign inSign up
View all cases

UPC CFI 166/2024

Apr 9, 2024·EP3805248: PROCESS FOR CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS THEREOF

Case details
Status
Case Closed
Action
Provisional measures
Category
Provisional Measures
Parties
Claimants
Reps: Kilian Seidel
Respondents
Reps: Emilia Zalewska
Division
Dusseldorf LD
Judges
Technology
Organic Chemistry
Language
English
Documents
Document titleDatePublic
Case Closure Formal Check2025-03-27Not public
Headnote-and-Keywords2024-09-06Not public
Measures_DecisionOutcome_Notification.pdf2024-09-06Not public
Final Order on PI Application2024-09-06Public
Final Order on PI Application2024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S012024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S022024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S032024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S032024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S012024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S042024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S022024-09-06Not public
18551-2024_OH_DUS-LOC_UPC202407310930AM_S042024-09-06Not public
Receipt2024-09-03Not public
Exhibit FBD 462024-09-03Not public
Submission of EPO preliminary opinion2024-09-03Not public
Time limits for parties' oral submissions2024-07-24Public
Acknowledgement-of-lodging2024-06-27Not public
BB42 Witness Statement Annelies van Leeuwen2024-06-27Not public
BB41 Witness Statement Bart Buiks2024-06-27Not public
20240627 Rejoinder UPC Celltrion v Novartis (signed)2024-06-27Not public
BB45b Annexes to expert declaration of Prof. dr. T. Dingermann2024-06-27Not public
BB44 Expert declaration Prof. dr. H.W. Frijlink of 26 June 2024 (Expert declaration of Prof. dr. H.W. Frijlink II)2024-06-27Not public
BB38 Higher Regional Court Dusseldorf judgment of 2009 2012 (I 2 U 44 12)2024-06-27Not public
BB45a CV of Prof. dr. T. Dingermann2024-06-27Not public
BB47 Presta et al J Immunol 1993 Vol 151 No 5 p 2623 26322024-06-27Not public
BB43 Witness Statement of DongKyu Kim2024-06-27Not public
BB38a English machine translation of Exhibit BB382024-06-27Not public
BB46 Cacia et al Biochemistry 1996 Vol 35 No 6 p 1897 1903.pdf2024-06-27Not public
BB39 Witness Statement Taeksang Kwon2024-06-27Not public
BB49 Expert declaration Dr. L. de Leede of 26 June 20242024-06-27Not public
BB40 Witness Statement Joel van Ruyskensvelde2024-06-27Not public
BB49b Annexes to expert declaration dr. L. de Leede of 26 June 20242024-06-27Not public
BB48 Notice from the EPO regarding accelerated proceedings of 17 June 20242024-06-27Not public
BB43a Exhibit 1 to Witness Statement of Dongkyu Kim2024-06-27Not public
BB49a CV of Dr. L. de Leede2024-06-27Not public
BB45 Expert declaration Prof. dr. T. Dingermann of 26 June 20242024-06-27Not public
BB44a Annexes to Expert declaration of Prof. dr. H.W. Frijlink II2024-06-27Not public
Outcome of the Order2024-06-14Not public
2024-06-14 Procedural Order (declaration)2024-06-14Public
Receipt2024-06-07Not public
Receipt2024-06-07Not public
Application pursuant to R. 262.2 RoP UPC2024-06-07Not public
Exhibit FBD 352024-06-07Not public
Exhibit FBD 45a2024-06-07Not public
Exhibit FBD 432024-06-07Not public
24-06-06 - Xolair - EP 248 - vs. Celltrion Inc. - Reply2024-06-07Not public
Exhibit FBD 37 (CONF)2024-06-07Not public
Exhibit FBD 442024-06-07Not public
Exhibit FBD 452024-06-07Not public
Exhibit FBD 422024-06-07Not public
Exhibit FBD 342024-06-07Not public
24-06-06 - Xolair - EP 248 - vs. Celltrion Inc. - Reply2024-06-07Not public
Exhibit FBD 36 (CONF)2024-06-07Not public
Exhibit FBD 39 (CONF)2024-06-07Not public
Exhibit FBD 40 (CONF)2024-06-07Not public
Application pursuant to R. 9 RoP UPC2024-06-07Not public
Exhibit FBD 412024-06-07Not public
Exhibit FBD 37 (CONF)2024-06-07Not public
Exhibit FBD 40 (CONF)2024-06-07Not public
Exhibit FBD 38 (CONF)2024-06-07Not public
Exhibit FBD 36a (CONF)2024-06-07Not public
Exhibit FBD 39 (CONF)2024-06-07Not public
Exhibit FBD 36a (CONF)2024-06-07Not public
Exhibit FBD 36 (CONF)2024-06-07Not public
Exhibit FBD 38 (CONF)2024-06-07Not public
summons2024-05-16Not public
Procedural Order Oral Hearing2024-05-16Public
Document technical reasons2024-05-16Public
Panel-Appointment2024-05-16Not public
BB35A - JP H04-198195 - translation of description2024-05-14Not public
BB30 - Crommelin Pharmaceutical Biotechnology Fundamentals and Applications (second edition)2024-05-14Not public
BB26K - Yadav et al. Pharmaceutical Research 2011 vol. 28 p. 1750-1764 submitted by letter of Novartis 26 July 2021 (Yad2024-05-14Not public
BB23 - EP 4 104 859 A12024-05-14Not public
BB27 - Statement of Defence by Novartis in the Dutch proceedings 3 April 20242024-05-14Not public
BB36 - Hernandez et al. 20222024-05-14Not public
BB26I - Tomar et al. journal of the Taylor Francis Group 2017 vol. 9 p. 476-489 submitted by letter of Novartis 26 July2024-05-14Not public
BB26M - Letter Novartis regarding third party observation 4 October 20212024-05-14Not public
BB21B - Annexes to the expert declaration of Prof. dr. H.W. Frijlink2024-05-14Not public
BB26E - European Search Opinion 10 June 20212024-05-14Not public
BB26A - International search report 12 April 20062024-05-14Not public
BB26B - Letter EPO to remedy deficiencies (submission of claims) 28 October 20202024-05-14Not public
BB26D - Letter Novartis on submission of claims 1-21 3 November 20202024-05-14Not public
BB21A - CV of Prof. dr. H.W. Frijlink2024-05-14Not public
BB20 - EP 2 116 265 B12024-05-14Not public
BB32 - EP 0 025 275 A22024-05-14Not public
BB26N - Notice Examiner 31 January 20222024-05-14Not public
BB37 - EP 1 786 830 B12024-05-14Not public
BB26H - Adjusted claims 1-3 by letter of Novartis 26 July 20212024-05-14Not public
BB27A - English machine translation of Statement of Defence by Novartis 3 April 20242024-05-14Not public
BB28 - Letter Novartis regarding submission of patentees 18 July 20222024-05-14Not public
BB29 - EP 1 610 820 B22024-05-14Not public
BB26O - Third party observation 24 May 20222024-05-14Not public
BB26J - Liu et al. Journal of Pharmaceutical Sciences 2005 vol. 94 p. 1928-1940 submitted by letter of Novartis 26 July2024-05-14Not public
BB25 - Decision of the Board of Appeal EPO on EP 636 5 May 20222024-05-14Not public
BB26C - Claims 1-21 submitted by letter of Novartis 3 November 20202024-05-14Not public
BB24 - EP 4 108 259 A12024-05-14Not public
BB26G - Letter Novartis regarding the adjustment of the claims 26 July 20212024-05-14Not public
BB21 - Expert declaration of Prof. dr. H.W. Frijlink on arginine(-HCl) (Expert declaration of Prof. Frijlink I)2024-05-14Not public
BB26F - European Search Report 31 May 20212024-05-14Not public
BB31 - Chen et al. Pharmaceutical Research 2003 Vol. 20 No. 12 p. 1952-60 (Chen)2024-05-14Not public
BB22 - Technical primer for the Patent2024-05-14Not public
20240515 Objection UPC Celltrion v Novartis (signed)2024-05-14Not public
BB34 - WO 9006764 A12024-05-14Not public
BB33 - WO 03072060 A22024-05-14Not public
BB35 - JP H04-1981952024-05-14Not public
BB26L - Third party observation 22 September 20212024-05-14Not public
2024-05-13 Order TQJ2024-05-13Public
Consent to allocation of technically qualified judge2024-05-13Not public
Consent to allocation of technically qualified judge2024-05-13Not public
Consent to the appointment of a TQJ2024-05-10Not public
Pre Order TQJ2024-05-02Not public
Pre Order TQJ2024-05-02Not public
Repeated upload of order 10 April 20242024-05-02Not public
Date of a possible oral hearing2024-04-23Public
Acknowledgement of access to case2024-04-18Not public
Confirmation of notification of appointment2024-04-18Not public
Service to Celltrion Inc.2024-04-18Not public
Letter for Service2024-04-12Not public
Panel-Appointment2024-04-11Not public
R. 207.8 Order2024-04-10Public
Template-Order2024-04-10Not public
Panel-Appointment2024-04-10Not public
Application-For-Measures-Receipt2024-04-10Not public
Formal-checks_Notification-of-positive-outcome2024-04-10Not public
Receipt2024-04-09Not public
Application to request confidentiality from the public (RoP262.2)2024-04-09Not public
Application-For-Measures-Acknowledgement2024-04-09Not public
Exhibit FBD 112024-04-09Not public
Exhibit FBD 222024-04-09Not public
Exhibit FBD 252024-04-09Not public
Exhibit FBD 332024-04-09Not public
Exhibit FBD 192024-04-09Not public
Exhibit FBD 72024-04-09Not public
Exhibit FBD 82024-04-09Not public
Exhibit FBD 5 (Confidential)2024-04-09Not public
Exhibit FBD 21-12024-04-09Not public
Exhibit FBD 302024-04-09Not public
Exhibit FBD 242024-04-09Not public
Exhibit FBD 62024-04-09Not public
Exhibit FBD 42024-04-09Not public
Application for Provisional Measures2024-04-09Not public
Exhibit FBD 162024-04-09Not public
Exhibit FBD 122024-04-09Not public
Exhibit FBD 102024-04-09Not public
Exhibit FBD 5 (Confidential)2024-04-09Not public
Exhibit FBD 22024-04-09Not public
Exhibit FBD 282024-04-09Not public
Exhibit FBD 122024-04-09Not public
Application for Provisional Measures2024-04-09Not public
Exhibit FBD 132024-04-09Not public
Exhibit FBD 212024-04-09Not public
Exhibit FBD 202024-04-09Not public
Exhibit FBD 262024-04-09Not public
Exhibit FBD 152024-04-09Not public
Exhibit FBD 142024-04-09Not public
Exhibit FBD 322024-04-09Not public
Exhibit FBD 272024-04-09Not public
Exhibit FBD 182024-04-09Not public
Exhibit FBD 92024-04-09Not public
Exhibit FBD 232024-04-09Not public
Exhibit FBD 32024-04-09Not public
Exhibit FBD 172024-04-09Not public
Exhibit FBD 312024-04-09Not public
Exhibit FBD 12024-04-09Not public
Exhibit FBD 292024-04-09Not public